India CMO raw material pharmaceutical industry

Custom Synthesis ,The pharmaceutical industry has almost all the advantages of outsourcing processing, whether in the production management, or in research and development, cost, technology, process, India has become CMO raw material drug production power.

India obtained COS certification, through the FDA DMF review of the CMO API production enterprises are 4 times times and 3 times times the number of our country. For example, India is the country with the largest number of valid document numbers, excluding U.S. companies, in the three-quarter 2005-year-old U.S. FDA-approved CMO BPC.

Compared with India, China’s advantages are more reflected in the business environment, infrastructure, economic stability, but in the outsourcing business direct experience, information technology management, international certification, personnel English proficiency, technical services, social credibility and so on.

The main factor of the advantage of India is that the overall software environment is good, including the protection of private property rights, the protection of intellectual property rights, the sound of legal system and the perfect media supervision, which are the most favorable soft environments to attract foreign capital. In addition, multinational pharmaceutical enterprises will be merged into China’s domestic related enterprises, even for the protection of intellectual property rights and other reasons directly set up factories, thus forming a new competition.

As February 23, 2006, the internationally renowned pharmaceutical company Novartis pharmaceutical companies in Changshu, Jiangsu, China, the construction of the first CMO raw material drug production and development base is officially laid foundation, the base will undoubtedly become a global industrial value chain of Novartis important components.